Enveric Biosciences Reports Results From Preclinical Studies On Metabolic Profile Of Lead Candidate EB-373
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences has reported results from preclinical studies on the metabolic profile of its lead candidate EB-373. The ADME and toxicology assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin, consistent with previously reported animal pharmacokinetic studies.
July 24, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences' positive preclinical results for EB-373 could potentially boost investor confidence and have a positive impact on its stock price.
Positive preclinical results are often seen as a positive indicator of a drug's potential success, which can increase investor confidence and potentially lead to an increase in the company's stock price. However, it's important to note that these are preclinical results and the drug still has to go through clinical trials.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100